Belantamab (Anti-TNFRSF17 / BCMA / CD269)

Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) found on the surface of cancer cells that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. The Belantamab mafodotin, sold under the brand name Blenrep, is a monoclonal antibody Belantamab conjugated with a cytotoxic agent (MMAF)through a linker. It’s used for treating relapsed and refractory multiple myeloma, particularly in patients who have undergone at least four prior therapies. This biosimilar antibody is used for research only. MW: 145.5 KD.

Product Details
Species Reactivity	Human
Host/Isotype	Human IgG1
Class	Monoclonal
Type	Recombinant Antibody
Immunogen	Human BCMA
Clone	Belantamab biosimilar
Conjugate	Unconjugated
Purity	99%
Molecular Weight	145.5 KD
Protein Concentration	1mg/ml
Storage Condition	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Storage Buffer	100mM Pro-Ac, 20mM Arg-Ac, pH 5.0